To the Editor A solid evidence base for appropriate antithrombotic therapy in patients with complex transcatheter aortic valve replacement (TAVR) is not yet established. This is especially important because approximately 40% of patients with TAVR from both the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) registry1 and the Placement of Aortic Transcatheter Valves (PARTNER) trial2 cohorts had baseline diagnosis of atrial fibrillation (AF) and may have had an indication for anticoagulation in addition to the protocol-directed 6 months of dual antiplatelet therapy (clopidogrel and aspirin) after TAVR.
Hough A, Woods D. Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. JAMA. 2014;311(12):1249-1250. doi:10.1001/jama.2014.1180